Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AmVac, Ascension GmbH, Helmholtz Center for Infection Research, Max Planck Society deal

AmVac received an exclusive, worldwide license to develop and commercialize vaccines using a modified non-replicating Sendai virus from

Read the full 182 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE